THYROCARE Thyrocare Technologies Q3 FY25 results (Oct–Dec 2024) and concall
Thyrocare Technologies delivered strong Q3 FY25 results, marked by robust revenue growth across its franchisee and partnership businesses, significant volume expansion, and improved margins. Strategic acquisitions like Polo Labs and Vimta Labs contributed to inorganic growth, though Vimta Labs is currently operating at a loss. The company also achieved full NABL accreditation, reinforcing its commitment to quality, and is expanding its service offerings and international footprint.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 177 | 166 |
| EBITDA | 48 | 42 |
| Net profit | 26 | 19 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
